Bacteriological and clinical studies with cefepime (CFPM), a new parenteral cephalosporin antibiotic were performed, yielding the following results. 1. Antimicrobial activity The MICs of CFPM against various clinical isolates were determined with an inoculum size of 106 cells/ml. The MIC80 was 3.13 μ/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, 0.05 for Escherichia coli, 0.20 for Klebsiella pneumoniae, 0.39 for Enterobacter spp. and Serratia marcescens, 0. 10 for Proteus spp., 0.78 for Citrobacter freundii, 6.25 for Acinetobacter calcoaceticus and 12.5 for Pseudomonas aeruginosa. Its activity against Gram-positive cocci was less than cefuzonam and cefmenoxime, but against Gram-negative rods, it was more active than ceftazidime, cefotaxime, cefmenoxime and cefuzonam. 2. Clinical efficacy One patient with pneumonia, 2 with purulent meningitis, 1 with sepsis, 1 with perianal abscess and 1 with ankylosing spondylitis were treated with CFPM at a daily dose of 2.0~4.0g for 3-17 days. Clinical response was excellent in 1, good in 1, fair in 1, poor in 2 and unknown in 1 patient. S. aureus, E. faecalis, Streptococcus milleri, Streptococcus mitis were eradicated by CFPM. No adverse reactions and no abnormal changes of laboratory investigations were observed.
|Number of pages||6|
|Publication status||Published - Jan 1 1991|
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Infectious Diseases
- Drug Discovery